Arcutis insider sells 4,504 shares to cover RSU taxes at ~$20

Rhea-AI Filing Summary

Larry Todd Edwards, EVP Chief Commercial Officer of Arcutis Biotherapeutics (ARQT), reported sales of 4,504 shares of common stock on 10/02/2025 to cover tax withholding arising from the vesting of Restricted Stock Units granted 2/22/2024. The sales were reported as two grouped transactions: 4,207 shares at a weighted average price of $19.9885 and 297 shares at a weighted average price of $20.7801. Following the transactions, beneficial ownership is reported at 179,324 shares. The filing also notes a purchase of 724 shares under the Employee Stock Purchase Plan on 5/31/2025. The seller certified the weighted‑average price ranges and offered to provide per‑trade details on request.

Positive

• Sale was for tax withholding on RSU vesting, indicating a non-speculative liquidity reason
• Reporting person retains substantial holdings after the sale (179,324 shares)
• Purchased 724 shares under ESPP on 5/31/2025, signalling continued participation in equity plan

Negative

• Insider disposed of 4,504 shares on 10/02/2025, reducing direct holdings
• Weighted average sale prices span ranges indicating multiple transactions (up to $20.995)

Insights

Insider Transactions Analyst

Sale was to cover tax on vested RSUs; size is modest relative to public float.

The reporting person executed sales totaling 4,504 shares on 10/02/2025

These disposals were explicitly made to satisfy tax withholding triggered by RSU vesting granted 2/22/2024, which suggests a routine liquidity event rather than a discretionary investment decision. The filing provides weighted average sale prices and the seller offers to disclose the per‑trade breakdown if requested.

The remaining beneficial ownership of 179,324 shares and a recent 724‑share ESPP purchase on 5/31/2025 show continued equity exposure. Monitor further scheduled vesting events or additional filings within the next 6–12 months for patterns of insider selling beyond tax‑covering transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Edwards Larry Todd

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CA 91361

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/02/2025		S		4,207(1)	D	$19.9885(2)	178,897	D
Common Stock	10/02/2025		S		297(1)	D	$20.7801(3)	179,324(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units granted on February 22, 2024.

2. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $19.545 to $20.502, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $20.5593 to $20.995, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

4. Includes 724 shares purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2025.

Remarks:

Reporting Person's title: EVP Chief Commercial Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Larry Todd Edwards	10/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ARQT insider Larry Todd Edwards report on Form 4?

He reported sales of 4,504 shares on 10/02/2025 to cover tax withholding from RSU vesting and a prior ESPP purchase of 724 shares on 5/31/2025.

Why were the shares sold according to the Form 4 for ARQT?

The filing states the sales were made to cover tax withholding obligations arising from the vesting of Restricted Stock Units granted on 2/22/2024.

How many shares does Larry Todd Edwards own after the reported transactions?

The Form 4 shows beneficial ownership of 179,324 shares following the reported sales.

What prices were the ARQT shares sold at in the Form 4?

Sales were reported as weighted averages: $19.9885 for 4,207 shares and $20.7801 for 297 shares; per‑trade prices ranged up to $20.995.

Does the Form 4 provide per‑trade sale details for ARQT?

The filer provides weighted average prices and offers to furnish per‑trade details on request to the SEC, issuer, or security holders.